Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

Background Beyond their potent LDL (low‐density lipoprotein) cholesterol (LDL‐C)–lowering efficacy (50–60%), PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors also reduce Lp(a) (lipoprotein[a]) levels by 25% to 30%, suggesting a 2:1 response ratio. We aimed to characterize the relatio...

Full description

Bibliographic Details
Main Authors: Michael D. Shapiro, Jessica Minnier, Hagai Tavori, Helina Kassahun, Andrea Flower, Ransi Somaratne, Sergio Fazio
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
lipid‐lowering therapy
lipoprotein[a]
low‐density lipoprotein cholesterol
proprotein convertase subtilisin/kexin type 9
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.118.010932

Similar Items

Similar Items